论文部分内容阅读
目的 研究乳腺癌组织中的 c- erb B- 2及突变型 p5 3癌基因和 ki- 6 7抗原表达与乳癌临床特点及激素受体关系 ,揭示 c- erb B- 2、 p5 3、 ki- 6 7表达对乳腺癌预后的评估意义。方法 应用 S- P免疫组化方法检测 5 7例乳腺癌组织中 c- erb B- 2、p5 3、ki- 6 7表达情况与临床病理参数的关系 ,结果作统计学分析。结果 ( 1 )在 5 7例乳腺癌组织中 ,c- erb B- 2、p5 3、ki- 6 7的阳性表达率分别为 6 3.2 % ( 36 / 5 7)、 4 2 .1 % ( 2 4 / 5 7)和 5 7.9% ( 33/ 5 7)。 ( 2 ) ki- 6 7表达随淋巴结转移率及肿瘤分期增加而增加。 ( 3) ER、 PR阳性患者的 c- erb B- 2的阳性表达明显低于 ER、 PR阴性患者。结论 乳腺癌 c- erb B- 2、 p5 3、 ki- 6 7的高表达与肿瘤浸润或转移密切相关 ,ER、 PR与 c- erb B- 2、p5 3、ki- 6 7这两种不同特性产物在乳腺癌组织中有一定的内在联系。因此 ,检测这些指标有助于判断乳腺癌的恶性度和生物学行为 ,确定术后治疗方案
Objective To investigate the relationship between the expression of c-erb B-2, mutant p5 3 oncogene and ki- 6 7 antigen in breast cancer and their clinicopathological features and hormone receptors, and to reveal the relationship between c-erb B- 2, p5 3, ki- 6 7 Expression of prognostic significance of breast cancer. Methods The expression of c-erb B-2, p5 3 and ki-67 in breast cancer tissues was detected by S-P immunohistochemistry. The relationship between the expression of c-erb and the clinicopathological parameters was analyzed. Results (1) The positive expression rates of c-erb B-2, p5 3 and k-6 7 in 67 breast cancer tissues were 62.2% (36/57) and 42.1% (2) 4/5 7) and 5 7.9% (33/57). (2) Ki-67 expression increased with lymph node metastasis and tumor stage. (3) The positive expression of c-erb B-2 in ER and PR positive patients was significantly lower than that in ER and PR negative patients. Conclusions The high expression of c-erb B-2, p5 3 and ki- 6 7 in breast cancer is closely related to the infiltration or metastasis of tumor. The differences of ER, PR and c-erb B- 2, p5 3 and ki- The characteristic product has a certain intrinsic relationship in breast cancer tissue. Therefore, the detection of these indicators will help determine the malignancy and biological behavior of breast cancer, to determine postoperative treatment options